Intellectual Property Licensing
•217 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (217)
| Company | Market Cap | Price |
|---|---|---|
|
SAVA
Cassava Sciences, Inc.
Exclusive license agreement with Yale University — IP Licensing activity directly related to simufilam.
|
$154.10M |
$3.22
-3.01%
|
|
BDTX
Black Diamond Therapeutics, Inc.
Licensing of BDTX-4933 to Servier constitutes Intellectual Property Licensing activity.
|
$152.02M |
$2.67
-1.66%
|
|
SGMO
Sangamo Therapeutics, Inc.
Licensing of STAC-BBB capsid and related IP provides non-dilutive funding and IP monetization.
|
$149.62M |
$0.50
-5.68%
|
|
GCL
GCL Global Holdings Ltd Ordinary Shares
GCL monetizes game IP via publishing and licensing arrangements, including developing and licensing IP.
|
$145.16M |
$1.20
-1.24%
|
|
CTW
CTW Cayman Class A Ordinary Shares
CTW leverages IP-based anime content and licenses IP for game development, representing IP licensing activity.
|
$134.19M |
$2.08
-0.95%
|
|
VTGN
VistaGen Therapeutics, Inc.
Company monetizes through licensing and sublicensing agreements, constituting an IP licensing business activity.
|
$132.85M |
$4.20
-1.99%
|
|
SVCO
Silvaco Group, Inc. Common Stock
Intellectual Property Licensing for semiconductor SIP IP that Silvaco licenses to customers.
|
$122.14M |
$4.06
-8.76%
|
|
LODE
Comstock Inc.
Strategic licensing of decarbonization technologies and related IP.
|
$121.81M |
$3.42
-8.67%
|
|
IKT
Inhibikase Therapeutics, Inc.
Company holds intellectual property and licensing activities around its programs (IKT-001Pro and risvodetinib).
|
$111.77M |
$1.50
-0.99%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed engages in licensing and royalty arrangements for intellectual property (e.g., HTIT license), making Intellectual Property Licensing a relevant revenue/operational theme.
|
$110.30M |
$2.73
+0.37%
|
|
ACOG
Alpha Cognition Inc. Common Stock
Alpha Cognition engages in IP licensing (e.g., ALPHA-1062 platform and Asia-Pacific rights).
|
$105.53M |
$6.50
+2.12%
|
|
HLVX
HilleVax, Inc.
Involves licensing of intellectual property related to vaccine candidates (e.g., HIL-216.00).
|
$104.79M |
$2.09
|
|
QUIK
QuickLogic Corporation
Core business is licensing eFPGA/Hard IP cores (IP licensing) to customers for integration into ASICs/SoCs/chiplets.
|
$103.33M |
$6.33
-1.56%
|
|
RPTX
Repare Therapeutics Inc.
The company monetizes IP via licensing out platforms and assets (Intellectual Property Licensing).
|
$95.15M |
$2.21
-0.67%
|
|
BIOX
Bioceres Crop Solutions Corp.
HB4 trait licensing and royalty monetization imply an IP licensing business line.
|
$94.18M |
$1.53
-2.85%
|
|
WNDW
SolarWindow Technologies, Inc.
The company signals licensing and IP-driven partnerships as a path to commercialization, relevant to Intellectual Property Licensing.
|
$91.59M |
$0.45
|
|
AOUT
American Outdoor Brands, Inc.
The company emphasizes IP protection and pending patents, enabling IP licensing activity.
|
$90.71M |
$7.13
+1.13%
|
|
CBUS
Cibus, Inc.
Business model includes licensing of gene-edited traits and IP to seed companies with royalty streams.
|
$88.95M |
$1.62
+0.62%
|
|
GAIA
Gaia, Inc.
Gaia retains worldwide rights to content/IP, enabling licensing to partners and platforms.
|
$88.64M |
$3.62
+8.06%
|
|
FLCX
flooidCX Corp.
Intellectual property licensing is a key revenue stream via licensed distributorships and patent-pending tech.
|
$87.50M |
$0.00
|
|
VTVT
vTv Therapeutics Inc.
The company relies on IP protection and licensing (e.g., Novo Nordisk background; patent allowance through 2041), fitting the 'Intellectual Property Licensing' theme as a core strategic asset.
|
$87.37M |
$27.51
+0.51%
|
|
NIKA
Nika Pharmaceuticals Inc.
Holds exclusive rights to ITV-1 and IPF-related technologies, aligning with Intellectual Property Licensing.
|
$85.13M |
$0.25
|
|
FBIO
Fortress Biotech, Inc.
Royalty/IP-based value streams (e.g., licensing-related milestones) align with Intellectual Property Licensing.
|
$84.21M |
$2.83
+2.73%
|
|
VHC
VirnetX Holding Corp
The company monetizes its patent portfolio through Intellectual Property Licensing.
|
$79.25M |
$19.39
+1.47%
|
|
ATOM
Atomera Incorporated
Atomera licenses MST intellectual property, generating revenue primarily through IP licensing and royalties.
|
$78.39M |
$2.60
+3.39%
|
|
VRDR
Verde Resources, Inc.
VRDR engages in IP licensing and technology transfer related to Verde Net Zero Blueprint and binder/biochar asphalt designs.
|
$77.01M |
$0.06
|
|
NIPG
NIP Group Inc.
Intellectual property licensing related to IP in the gaming/digital entertainment ecosystem.
|
$75.68M |
$1.36
|
|
ZTEK
Zentek Ltd.
Zentek operates as an intellectual property technology development and commercialization company, implying IP licensing activities.
|
$74.54M |
$0.73
-3.37%
|
|
NLST
Netlist, Inc.
Netlist's core strategy is monetizing its IP portfolio through licensing revenues and patent damages.
|
$63.96M |
$0.72
|
|
GLXZ
Galaxy Gaming, Inc.
Galaxy Gaming licenses proprietary casino table game IP and related tech (e.g., Bonus Jackpot System) to operators; core IP licensing business.
|
$61.15M |
$2.77
|
|
ABVC
ABVC BioPharma, Inc.
ABVC engages in IP licensing through agreements and patents (e.g., Japan patent for ABV-1504) and partnerships.
|
$56.74M |
$2.35
-6.92%
|
|
LVO
LiveOne, Inc.
Intellectual Property Licensing: monetization of LiveOne's IP and technology assets.
|
$56.52M |
$4.90
+6.29%
|
|
QSEP
QS Energy, Inc.
Temple University licenses underpinning the AOT technology imply an Intellectual Property Licensing aspect to the business.
|
$56.25M |
$0.17
|
|
REFR
Research Frontiers Incorporated
SPD-SmartGlass licensing is the core revenue model via IP licensing.
|
$54.51M |
$1.56
-0.32%
|
|
LEAT
Leatt Corporation
Leatt licenses its Leatt-Brace IP and earns royalty income from licensed products, representing an intellectual property licensing revenue stream.
|
$54.14M |
$9.97
|
|
CELU
Celularity Inc.
Celularity monetized IP and entered an exclusive, royalty-bearing license for the sold IP with a repurchase option.
|
$52.85M |
$1.95
-1.42%
|
|
LOOP
Loop Industries, Inc.
Revenue stream from licensing Loop's intellectual property and core technology.
|
$52.01M |
$1.10
+0.92%
|
|
RPMT
Rego Payment Architectures, Inc.
RPMT owns and licenses intellectual property/patents central to its platform technology.
|
$46.73M |
$0.38
|
|
LVTX
LAVA Therapeutics N.V.
LAVA engages in IP licensing and asset monetization (including CVRs and collaborations with Pfizer/J&J).
|
$45.76M |
$1.65
-5.17%
|
|
TENX
Tenax Therapeutics, Inc.
Tenax holds exclusive rights to levosimendan in the US/Canada, a core IP/licensing aspect of its business model.
|
$44.03M |
$9.77
+4.49%
|
|
HOWL
Werewolf Therapeutics, Inc.
Global Jazz collaboration/licensing of JZP898 constitutes Intellectual Property Licensing activity.
|
$43.52M |
$0.97
-2.85%
|
|
RAIN
Rain Enhancement Technologies Holdco Inc
The company relies on exclusive IP licensing for weather modification patents and related engineering designs.
|
$41.42M |
$5.46
|
|
NEON
Neonode Inc.
Neonode's core business is licensing its IP and monetizing via royalties.
|
$39.27M |
$2.39
-2.85%
|
|
VNCE
Vince Holding Corp.
Licensing of Vince's brand IP constitutes a brand/IP licensing revenue stream.
|
$38.24M |
$2.91
+1.04%
|
|
PXLW
Pixelworks, Inc.
Pixelworks monetizes IP licensing for its proprietary visual processing technology.
|
$36.87M |
$6.87
-0.51%
|
|
TOON
Kartoon Studios Inc.
Ownership and monetization of Stan Lee Universe and other IP assets through licensing.
|
$36.42M |
$0.76
+2.28%
|
|
SNAL
Snail, Inc. Class A Common Stock
Intellectual property licensing of the ARK IP to related party and partners.
|
$35.53M |
$0.92
+7.67%
|
|
LNZA
LanzaTech Global, Inc.
The company licenses its proprietary gas fermentation technology, a form of IP licensing.
|
$35.02M |
$14.76
+1.06%
|
|
RMCO
Royalty Management Holding Corporation
RMCO monetizes through intellectual property licensing and royalty rights on technology and IP assets.
|
$34.16M |
$2.60
+3.17%
|
|
NXTC
NextCure, Inc.
The company engages in licensing of its IP (e.g., SIM0505 outside territory), representing IP Licensing activities.
|
$33.01M |
$12.40
-2.59%
|
|
NTIP
Network-1 Technologies, Inc.
NTIP's core business is acquiring and monetizing patents via licensing and settlements, i.e., Intellectual Property Licensing.
|
$32.59M |
$1.43
-0.69%
|
|
APLT
Applied Therapeutics, Inc.
The company out-licensing AT-001 and engages in IP licensing arrangements for its assets, indicating intellectual property licensing activity.
|
$31.19M |
$0.22
-4.26%
|
|
XCUR
Exicure, Inc.
License/royalty arrangements for cavrotolimod IP indicate Intellectual Property Licensing activity.
|
$30.96M |
$5.58
-17.28%
|
|
VPLM
Voip-Pal.com Inc.
VoIP-Pal monetizes a portfolio of VoIP-related patents primarily via licensing and patent enforcement, directly aligning with Intellectual Property Licensing.
|
$29.05M |
$0.01
|
|
HCMC
Healthier Choices Management Corp.
HCMC monetizes its patent portfolio (Q-Cup, Imitine) through licensing and enforcement activities, constituting an Intellectual Property Licensing business line.
|
$24.06M |
$0.00
|
|
TSE
Trinseo PLC
Licensing income from polycarbonate technology shows a direct IP licensing revenue line.
|
$23.96M |
$0.66
-5.28%
|
|
IBIO
iBio, Inc.
iBio engages in Intellectual Property Licensing (e.g., exclusive rights licensed to AstralBio), a core monetization channel.
|
$21.62M |
$1.10
+0.45%
|
|
NAII
Natural Alternatives International, Inc.
Licensing of NAII's proprietary beta-alanine IP (CarnoSyn, SR CarnoSyn, TriBsyn) generating licensing-related revenue.
|
$21.43M |
$3.31
-4.06%
|
|
ITRM
Iterum Therapeutics plc
The company holds and leverages intellectual property around ORLYNVAH (sulopenem) and engages in licensing-related IP activities.
|
$21.08M |
$0.47
+7.80%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria emphasizes its growing patent portfolio and licensing of its technology, indicating IP licensing as a core revenue stream.
|
$20.73M |
$1.09
-2.23%
|
|
TXMD
TherapeuticsMD, Inc.
TXMD's core business model is licensing pharmaceutical IP and collecting royalties from partners for licensed women's health products.
|
$20.14M |
$1.68
+4.35%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
NIH Patent License Agreement provides exclusive rights to NIH-derived IP related to LB-100, representing a material intellectual property licensing asset.
|
$18.47M |
$4.13
-2.71%
|
|
FGI
FGI Industries Ltd.
FlushGuard anti-overflow toilet technology is licensed, aligning with Intellectual Property Licensing.
|
$17.30M |
$9.12
+26.47%
|
|
LPCN
Lipocine Inc.
TLANDO is being commercialized through IP licensing agreements (e.g., Verity, regional partners), reflecting an Intellectual Property Licensing business model.
|
$17.07M |
$3.26
+5.16%
|
|
GIGM
GigaMedia Limited
GigaMedia owns/provides IP rights for its games/platforms; IP licensing is a revenue stream.
|
$16.87M |
$1.53
+2.33%
|
|
CRIS
Curis, Inc.
Curis monetizes intellectual property via licensing (e.g., Hedgehog pathway tech and Erivedge royalties).
|
$16.87M |
$1.36
+0.74%
|
|
NNUP
Nocopi Technologies, Inc.
NNUP licenses its reactive ink technologies and related IP, making Intellectual Property Licensing a core revenue channel.
|
$16.33M |
$1.51
|
|
KNW
Know Labs, Inc.
Intellectual property licensing as a primary strategic revenue channel via KTL.
|
$16.05M |
$2.14
|
|
APHP
American Picture House Corporation
Engages in IP licensing and related rights monetization (Intellectual Property Licensing).
|
$15.89M |
$0.14
|
|
PETV
PetVivo Holdings, Inc.
Licensing of IP related to Precise PRP suggests Intellectual Property Licensing as a revenue/strategy channel.
|
$15.84M |
$1.09
|
|
ALDS
APPlife Digital Solutions, Inc.
Acquired LeSalon IP supports IP licensing and monetization.
|
$15.80M |
$0.01
|
|
SQNS
Sequans Communications S.A.
Sequans is building licensing revenue from its 5G IP, including TORUS/eRedCap, and ACP RF IP.
|
$15.80M |
$6.25
-4.94%
|
|
PULM
Pulmatrix, Inc.
The company monetizes its IP (iSPERSE and related assets) through licensing and royalties, a direct service/product offering.
|
$14.90M |
$4.00
-6.32%
|
|
MSGM
Motorsport Games Inc.
MSGM owns proprietary IP (e.g., Le Mans Ultimate) and monetizes via IP licensing arrangements.
|
$14.85M |
$2.62
-6.09%
|
|
AGAE
Allied Gaming & Entertainment Inc.
GAE holds and licenses intellectual property (e.g., Z-Tech IP, Angry Birds collaboration), creating an IP licensing business line.
|
$13.53M |
$0.35
-0.34%
|
|
MGRX
Mangoceuticals, Inc.
Intellectual property licensing for acquired patents and technology.
|
$11.59M |
$1.10
-6.36%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Company holds exclusive worldwide licenses to drug programs/assets, representing IP licensing as a revenue/asset strategy.
|
$11.39M |
$1.13
-1.74%
|
|
GELS
Gelteq Limited Ordinary Shares
The company licenses its patent-pending gel delivery technology to partners, making Intellectual Property Licensing a central revenue model.
|
$10.29M |
$1.10
|
|
AQMS
Aqua Metals, Inc.
Plans to license AquaRefining technology to partners, indicating IP licensing as a core growth vector.
|
$10.11M |
$7.46
-0.80%
|
|
RVYL
Ryvyl Inc.
Intellectual Property Licensing; licensing of core technology/IP components to customers/partners.
|
$9.90M |
$0.32
-5.37%
|
|
DSS
DSS, Inc.
Company licenses intellectual property and technologies (IP Licensing) including AuthentiGuard and biotech assets.
|
$9.44M |
$1.02
+2.00%
|
|
VYNE
VYNE Therapeutics Inc.
Company has an exclusive worldwide license for a BET inhibitor library, constituting Intellectual Property Licensing.
|
$9.42M |
$0.38
+0.77%
|
|
LGVN
Longeveron Inc.
Longeveron licensed iPSC technology, representing Intellectual Property Licensing activity.
|
$9.33M |
$0.62
-2.29%
|
|
BRTX
BioRestorative Therapies, Inc.
The company maintains a comprehensive patent portfolio and discusses licensing, indicating potential IP licensing as a revenue channel.
|
$8.86M |
$1.14
+2.25%
|
|
SEED
Origin Agritech Limited
Significant licensing of biotechnology traits and IP (GMO/gene-editing assets) to partners, reflecting IP licensing activity.
|
$8.84M |
$1.41
-0.35%
|
|
KIDZ
Classover Holdings, Inc. Class B Common Stock
Acquisition of an AI IP portfolio and potential licensing of AI technologies.
|
$7.60M |
$0.32
+0.16%
|
|
BMRA
Biomerica, Inc.
Intellectual Property Licensing leveraging Biomerica's patent portfolio and licensing opportunities.
|
$6.59M |
$2.35
+1.82%
|
|
SBFM
Sunshine Biopharma, Inc.
The company engages in exclusive intellectual property licensing arrangements with external entities.
|
$6.52M |
$1.47
+2.08%
|
|
VS
Versus Systems Inc.
Licensing Versus Systems' proprietary gamification and engagement technology as IP to ASPIS Cyber Technologies provides the licensing revenue.
|
$6.42M |
$1.29
-1.89%
|
|
ATNF
ETHZilla Corporation Common Stock
Monetization of legacy biotech IP via licensing and maintenance.
|
$6.35M |
$10.51
|
|
KAVL
Kaival Brands Innovations Group, Inc.
GoFire intellectual property and its monetization/royalties constitute an Intellectual Property Licensing business line.
|
$5.71M |
$0.49
+2.14%
|
|
CYCN
Cyclerion Therapeutics, Inc.
The company monetizes its intellectual property through licensing deals and milestone-based payments.
|
$5.61M |
$1.70
-0.29%
|
|
ALBT
Avalon GloboCare Corp.
QTY code protein design IP constitutes an Intellectual Property Licensing asset with potential monetization value.
|
$5.60M |
$1.50
+2.74%
|
|
IBO
Impact BioMedical Inc.
Impact BioMedical monetizes its IP via licensing agreements, constituting Intellectual Property Licensing.
|
$5.58M |
$0.46
-2.13%
|
|
PRKR
ParkerVision, Inc.
ParkerVision's core business is licensing and monetizing its RF patent portfolio, i.e., intellectual property licensing.
|
$5.55M |
$0.23
|
|
BUDZ
WEED, Inc.
Potential licensing of proprietary cannabis/genomics IP and related technologies.
|
$5.44M |
$0.04
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Business model includes licensing of intellectual property (hCDR1) via collaborations (e.g., with Yeda).
|
$4.63M |
$0.84
-3.70%
|
|
XELB
Xcel Brands, Inc.
Licensing of intellectual property (brand IP) to licensees generating royalties.
|
$4.61M |
$0.91
-2.03%
|
|
MAXN
Maxeon Solar Technologies, Ltd.
The content highlights monetization of an extensive IP portfolio and licensing arrangements.
|
$4.52M |
$3.01
+0.67%
|
|
HIGR
Hi-Great Group Holding Company
Exclusive worldwide IP licensing for KRAS gene assets represents a major monetization/licensing channel.
|
$4.36M |
$0.04
|
Showing page 2 of 3 (217 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
